Immunotoxin Against a Donor MHC Class II Molecule Induces Indefinite Survival of Murine Kidney Allografts

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
K BrownW Wong

Abstract

Rejection of donor organs depends on the trafficking of donor passenger leukocytes to the secondary lymphoid organs of the recipient to elicit an immune response via the direct antigen presentation pathway. Therefore, the depletion of passenger leukocytes may be clinically applicable as a strategy to improve graft survival. Because major histocompatibility complex (MHC) class II(+) cells are most efficient at inducing immune responses, selective depletion of this population from donor grafts may dampen the alloimmune response and prolong graft survival. In a fully MHC mismatched mouse kidney allograft model, we describe the synthesis of an immunotoxin, consisting of the F(ab')2 fragment of a monoclonal antibody against the donor MHC class II molecule I-A(k) conjugated with the plant-derived ribosomal inactivating protein gelonin. This anti-I-A(k) gelonin immunotoxin depletes I-A(k) expressing cells specifically in vitro and in vivo. When given to recipients of kidney allografts, it resulted in indefinite graft survival with normal graft function, presence of Foxp3(+) cells within donor grafts, diminished donor-specific antibody formation, and delayed rejection of subsequent donor-type skin grafts. Strategies aimed at the donor ...Continue Reading

References

Sep 1, 1991·Transplant International : Official Journal of the European Society for Organ Transplantation·M KrzymańskiW Müller-Ruchholtz
Jun 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·D L FaustmanP E Lacy
Dec 1, 1994·Cancer Immunology, Immunotherapy : CII·K J McGrawD A Scheinberg
Jan 1, 1996·Transplant International : Official Journal of the European Society for Organ Transplantation·Y ShimizuN Kamada
Sep 1, 1999·Microsurgery·W R HanP L Mottram
Jan 6, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E J SuchinL A Turka
Oct 7, 1958·Annals of the New York Academy of Sciences·C A STETSON, R DEMOPOULOS
Jul 30, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul J MartinEllen S Vitetta
Aug 24, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Daniel KreiselBruce R Rosengard
Mar 21, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nicolas DegauqueSophie Brouard
Jul 1, 1948·Stain Technology·J F A McMANUS
Mar 26, 2011·The American Journal of Pathology·Masahiro MiyajimaRobert B Colvin
Mar 7, 2014·Cell Transplantation·Sang C LeeByungsuk Kwon

❮ Previous
Next ❯

Citations

Dec 3, 2016·Current Transplantation Reports·Dominic A BoardmanRobert I Lechler
Jul 1, 2020·Frontiers in Immunology·Yanzhi JiangXiao-Kang Li

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Software Mentioned

Cellquest

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.